Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis

被引:50
作者
Ratner, Paul H. [1 ]
Meltzer, Eli O. [2 ]
Teper, Ariel [3 ]
机构
[1] Sylvana Res Associates, San Antonio, TX 78229 USA
[2] Univ Calif San Diego, Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA
[3] Schering Plough Res Inst, Kenilworth, NJ USA
关键词
Mometasone furoate; Allergic rhinitis; Intranasal corticosteroids; Long-term safety; PITUITARY-ADRENAL AXIS; INTRANASAL FLUTICASONE PROPIONATE; JOINT TASK-FORCE; QUALITY-OF-LIFE; BECLOMETHASONE DIPROPIONATE; OTITIS-MEDIA; BRONCHIAL RESPONSIVENESS; GROWTH SUPPRESSION; BUDESONIDE; ASTHMA;
D O I
10.1016/j.ijporl.2008.12.025
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objective: Perennial allergic rhinitis (PAR) affects children at a Young age. Current guidelines recommend intranasal corticosteroids as the first-line treatment in patients with moderate-to-severe or persistent disease or in those who have congestion. In this study, the long-term safety and efficacy of mometasone furoate nasal spray (MFNS) were assessed in children with PAR. Methods: In this multicenter, active-controlled, evaluator-blind, 12-month study, 255 children aged 611 years with a >= 1-year history of PAR were randomized to receive once-daily MFNS 100 mu g (n = 166) or the active comparator beclomethasone dipropionate (BDP) 168 mu g (n = 85). Changes from baseline in overall PAR symptoms and response to treatment were rated at each visit. Cosyntropin stimulation testing, as well as tonometry and slit lamp procedures, were performed. Safety variables were assessed. Results: A total of 137 subjects in the MFNS group and 68 in the BDP group completed treatment. The mean reductions in physician-and subject-rated overall condition of PAR at week 52 were -42.1% and -39.7%, respectively, for MFNS, compared with -44.0% and -39.0%, respectively, for BDP. A total of 94% and 100% of MFNS and BDP subjects, respectively, reported adverse events (AEs), which were mostly mild or moderate. The most frequently reported treatment-related AEs in both groups were epistaxis, headache, and pharyngitis. Response to cosyntropin was normal and no posterior subcapsular cataracts were observed in either group. Although no significant changes in intraocular pressure were observed with MFNS, one subject receiving BDP demonstrated this effect. Conclusions: Treatment with MFNS 100 mu g once daily for 1 year was well tolerated in children 6-11 years old, with negligible systemic exposure and no evidence of suppression of the hypothalamic-pituitary-adrenal axis or ocular changes. (c) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:651 / 657
页数:7
相关论文
共 49 条
[1]  
*AG HEALTHC RES QU, 2002, 54 AG HEALTHC RES QU
[2]  
Allen DB, 2002, ALLERGY ASTHMA PROC, V23, P407
[3]   Sensitization to common allergens and its association with allergic disorders at age 4 years: A whole population birth cohort study [J].
Arshad, SH ;
Tariq, SM ;
Matthews, S ;
Hakim, E .
PEDIATRICS, 2001, 108 (02) :art. no.-e33
[4]   Allergic rhinitis in children: Diagnosis and management strategies [J].
Berger W.E. .
Pediatric Drugs, 2004, 6 (4) :233-250
[5]   The role of mometasone furoate aqueous nasal spray in the treatment of adenoidal hypertrophy in the pediatric age group: Preliminary results of a prospective, randomized study [J].
Berlucchi, Marco ;
Salsi, Daria ;
Valetti, Luisa ;
Parrinello, Giovanni ;
Nicolai, Piero .
PEDIATRICS, 2007, 119 (06) :E1392-E1397
[6]   Concerns about intranasal corticosteroids for overthe-counter use: position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology [J].
Bielory, L ;
Blaiss, M ;
Fineman, SM ;
Ledford, DK ;
Lieberman, P ;
Simons, FER ;
Skoner, DP ;
Storms, WW .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2006, 96 (04) :514-525
[7]   Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen) [J].
Bousquet, J. ;
Khaltaev, N. ;
Cruz, A. A. ;
Denburg, J. ;
Fokkens, W. J. ;
Togias, A. ;
Zuberbier, T. ;
Baena-Cagnani, C. E. ;
Canonica, G. W. ;
van Weel, C. ;
Agache, I. ;
Ait-Khaled, N. ;
Bachert, C. ;
Blaiss, M. S. ;
Bonini, S. ;
Boulet, L. -P. ;
Bousquet, P. -J. ;
Camargos, P. ;
Carlsen, K. -H. ;
Chen, Y. ;
Custovic, A. ;
Dahl, R. ;
Demoly, P. ;
Douagui, H. ;
Durham, S. R. ;
van Wijk, R. Gerth ;
Kalayci, O. ;
Kaliner, M. A. ;
Kim, Y. -Y. ;
Kowalski, M. L. ;
Kuna, P. ;
Le, L. T. T. ;
Lemiere, C. ;
Li, J. ;
Lockey, R. F. ;
Mavale-Manuel, S. ;
Meltzer, E. O. ;
Mohammad, Y. ;
Mullol, J. ;
Naclerio, R. ;
Hehir, R. E. O. ;
Ohta, K. ;
Ouedraogo, S. ;
Palkonen, S. ;
Papadopoulos, N. ;
Passalacqua, G. ;
Pawankar, R. ;
Popov, T. A. ;
Rabe, K. F. ;
Rosado-Pinto, J. .
ALLERGY, 2008, 63 :8-+
[8]   QUALITY-OF-LIFE IN ASTHMA .1. INTERNAL CONSISTENCY AND VALIDITY OF THE SF-36 QUESTIONNAIRE [J].
BOUSQUET, J ;
KNANI, J ;
DHIVERT, H ;
RICHARD, A ;
CHICOYE, A ;
WARE, JE ;
MICHEL, FB .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (02) :371-375
[9]  
Bousquet J., 2002, Allergy (Copenhagen), V57, P841, DOI 10.1034/j.1398-9995.2002.23625.x
[10]   Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children [J].
Brannan, MD ;
Herron, JM ;
Affrime, MB .
CLINICAL THERAPEUTICS, 1997, 19 (06) :1330-1339